ESMO Virtual Congress 2020 Prostate Cancer - Results from #20

Viewing 21-40 of 68 articles

ESMO Virtual Congress 2020: Invited Discussant: Accumulating Data and Experience in the Treatment of Metastatic Naïve/Sensitive Prostate Cancer

ESMO Virtual Congress 2020: Cabazitaxel Activity in Men with Metastatic Castration Resistant Prostate Cancer with and without DNA Damage Repair (DDR) Defects

ESMO Virtual Congress 2020: Novel, Oral Tubulin Inhibitor, in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Failed an Androgen Blocking Agent: Phase Ib/II Study of VERU-111

ESMO Virtual Congress 2020: Abiraterone Acetate Plus Prednisolone for Hormone-Naïve Prostate Cancer: Long-Term Results from Metastatic Patients in the STAMPEDE Randomized Trial

ESMO Virtual Congress 2020: Efficacy of BN-Brachyury + Bintrafusp Alfa + N-803 in Castration-Resistant Prostate Cancer: Results from a Preliminary Analysis of the Quick Efficacy Seeking Trial

ESMO Virtual Congress 2020: MANSMED: Repurposing Metformin as an Anticancer Drug: Preliminary Results of Randomized Controlled Trial in Advanced Prostate Cancer

ESMO VIrtual Congress 2020: Co-Occurrence of Actionable Gene Fusions and Microsatellite Instability-High in 20296 Solid Tumors: A Pan-Cancer Analysis

ESMO Virtual Congress 2020: Novel Immunotherapy for Prostate Cancer - AMG 160 - PSMA-Targeted, Bispecific T-Cell Engager (BiTE®) Immune Therapy for Metastatic Castration-Resistant Prostate Cancer - Invited Discussant

ESMO Virtual Congress 2020: AMG 160, a Half-Life Extended, PSMA-Targeted, Bispecific T-cell Engager (BiTE®) immune Therapy for mCRPC - Interim Results From a Phase I Study

ESMO Virtual Congress 2020: First Results from a Phase 1 Study of AMG 160, a Half-Life Extended, PSMA-Targeted, Bispecific T-Cell Engager (BiTE®) Immune Therapy for Metastatic Castration-Resistant Prostate Cancer

ESMO Virtual Congress 2020: Imaging Based Prostate Cancer Screening – First Results from a Prospective Screening Study for Prostate Cancer in Men with Germline BRCA Alterations Utilizing PSA and MRI

ESMO Virtual Congress 2020: Local Therapy to the Primary Tumour for Newly Diagnosed, Oligo-Metastatic Prostate Cancer: A Prospective Randomized, Phase II, Open-Label Trial

ESMO Virtual Congress 2020: High Activity of Nivolumab in Patients with Pathogenic Exonucleasic Domain POLE (edPOLE) Mutated Mismatch Repair Proficient Advanced Tumours

ESMO Virtual Congress 2020: The Final Overall Survival (OS) Analysis From the PROfound Study and IPATential150, Ipatasertib Plus Abiraterone (abi) vs Placebo Plus Abi in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Invited Discussion

ESMO Virtual Congress 2020: IPATential150: Phase III Study of Ipatasertib plus Abiraterone vs Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer

ESMO Virtual Congress 2020: The Final Overall Survival Analysis of the PROfound Study: Olaparib vs Physician’s Choice of Enzalutamide or Abiraterone in Patients with mCRPC and Homologous Recombination Repair Gene Alteration

ESMO Virtual Congress 2020: Real-World Treatment Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Mutations

ESMO Virtual Congress 2020: Pembrolizumab plus Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: KEYNOTE-365 Cohort C Update

ESMO Virtual Congress 2020: Fracture Risk in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223

ESMO Virtual Congress 2020: Impact of Abiraterone Acetate Plus Prednisone (AAP) in Patients with Castration-Sensitive Prostate Cancer (mCSPC) and Visceral Metastases: Subgroup Analyses of the LATITUDE study

1
2
3
4